CD3, CD20 Bispecifics: A New Frontier in DLBCL Treatment

News
Video

Dr. Lunning explores the FDA-approved CD3- and CD20-targeting bispecifics in relapsed/refractory DLBCL, highlighting their potential impact on heavily pretreated patients.

Recent Videos
Related Content